You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBuprenorphine
Accession NumberDB00921  (APRD00670)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational, Vet Approved
DescriptionBuprenorphine is a derivative of the opioid alkaloid thebaine that is a more potent (25 - 40 times) and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. [PubChem]
Structure
Thumb
Synonyms
(-)-Buprenorphine
(−)-buprenorphine
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
Buprenophine
Buprenorfina
Buprenorphinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BelbucaFilm75 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm600 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm150 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm750 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm300 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm900 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BelbucaFilm450 ug/1BuccalEndo Pharmaceuticals2015-06-01Not applicableUs
BuprenexInjection.3 mg/mLIntramuscular; IntravenousIndivior Inc.1985-06-30Not applicableUs
ButransPatch, extended release20 ug/hTransdermalPurdue Pharma LP2011-02-14Not applicableUs
ButransPatch, extended release10 ug/hTransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
ButransPatch, extended release20 ug/hTransdermalA S Medication Solutions Llc2011-02-14Not applicableUs
ButransPatch, extended release7.5 ug/hTransdermalPurdue Pharma LP2011-02-14Not applicableUs
ButransPatch, extended release20 ug/hTransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
ButransPatch, extended release5 ug/hTransdermalPurdue Pharma LP2011-02-14Not applicableUs
ButransPatch, extended release15 ug/hTransdermalPurdue Pharma LP2011-02-14Not applicableUs
ButransPatch, extended release5 ug/hTransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
ButransPatch, extended release10 ug/hTransdermalPurdue Pharma LP2011-02-14Not applicableUs
ButransPatch, extended release10 ug/hTransdermalA S Medication Solutions Llc2011-02-14Not applicableUs
Butrans 10Patch10 mcgTransdermalPurdue Pharma2010-05-26Not applicableCanada
Butrans 15Patch15 mcgTransdermalPurdue Pharma2016-06-15Not applicableCanada
Butrans 20Patch20 mcgTransdermalPurdue Pharma2010-05-26Not applicableCanada
Butrans 5Patch5 mcgTransdermalPurdue Pharma2010-05-26Not applicableCanada
ProbuphineImplant80 mg/1SubcutaneousBraeburn Pharmaceuticals2016-06-09Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BuprenorphineTablet2 mg/1SublingualTeva Pharmaceuticals Usa, Inc.2010-05-25Not applicableUs
BuprenorphineTablet8 mg/1SublingualSun Pharmaceutical Industries Limited2016-02-17Not applicableUs
BuprenorphineTablet8 mg/1SublingualTeva Pharmaceuticals Usa, Inc.2010-05-25Not applicableUs
BuprenorphineTablet8 mg/1SublingualActavis Pharma, Inc.2015-03-23Not applicableUs
BuprenorphineTablet2 mg/1SublingualREMEDYREPACK INC.2016-09-30Not applicableUs
BuprenorphineTablet2 mg/1SublingualSun Pharmaceutical Industries Limited2016-02-17Not applicableUs
BuprenorphineTablet2 mg/1SublingualActavis Pharma, Inc.2015-03-23Not applicableUs
BuprenorphineTablet8 mg/1SublingualREMEDYREPACK INC.2016-09-30Not applicableUs
Buprenorphine HClTablet8 mg/1SublingualLake Erie Medical DBA Quality Care Products LLC2009-10-08Not applicableUs
Buprenorphine HClTablet2 mg/1SublingualCardinal Health2009-10-08Not applicableUs
Buprenorphine HClTablet2 mg/1SublingualWest Ward Pharmaceuticals Corp.2009-10-08Not applicableUs
Buprenorphine HClTablet2 mg/1SublingualLake Erie Medical DBA Quality Care Products LLC2009-10-08Not applicableUs
Buprenorphine HClTablet8 mg/1SublingualWest Ward Pharmaceuticals Corp.2009-10-08Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualA S Medication Solutions Llc2010-09-24Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualHi Tech Pharmacal Co., Inc.2010-09-24Not applicableUs
Buprenorphine HydrochlorideInjection, solution.3 mg/mLIntramuscular; IntravenousHospira, Inc.2010-07-12Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualTYA Pharmaceuticals2010-09-24Not applicableUs
Buprenorphine HydrochlorideTablet2 mg/1OralREMEDYREPACK INC.2010-12-072016-10-13Us
Buprenorphine HydrochlorideTablet2 mg/1SublingualREMEDYREPACK INC.2013-07-25Not applicableUs
Buprenorphine HydrochlorideInjection, solution.324 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.2010-08-13Not applicableUs
Buprenorphine HydrochlorideTablet2 mg/1SublingualTYA Pharmaceuticals2010-09-24Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
Buprenorphine HydrochlorideTablet2 mg/1OralREMEDYREPACK INC.2010-12-07Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1Oralbryant ranch prepack2009-10-09Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualA S Medication Solutions2010-09-24Not applicableUs
Buprenorphine HydrochlorideInjection, solution.3 mg/mLIntramuscular; IntravenousRebel Distributors Corp2010-07-12Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualLake Erie Medical DBA Quality Care Products LLC2010-09-24Not applicableUs
Buprenorphine HydrochlorideTablet8 mg/1SublingualREMEDYREPACK INC.2013-06-242016-10-13Us
Buprenorphine HydrochlorideTablet2 mg/1SublingualHi Tech Pharmacal Co., Inc.2010-09-24Not applicableUs
Buprenorphine HydrochlorideInjection.324 mg/mLIntramuscular; IntravenousPar Pharmaceutical Inc.2015-07-30Not applicableUs
Buprenorphine Hydrochloride SublingualTablet2 mg/1SublingualMylan Pharmaceuticals Inc.2015-03-06Not applicableUs
Buprenorphine Hydrochloride SublingualTablet2 mg/1SublingualREMEDYREPACK INC.2016-05-04Not applicableUs
Buprenorphine Hydrochloride SublingualTablet8 mg/1SublingualMylan Pharmaceuticals Inc.2015-03-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AddnokRusan Pharma Ltd.
BuprelNot Available
BuprigesicNeon Laboratories
MorgesicSamarth Pharma
NorphinUnichem Laboratories
NorspanNot Available
ProbuphineTitan Pharmaceuticals, Inc.
SubutexNot Available
TemgesicNot Available
TidigesicSun Pharmaceuticals
Brand mixtures
NameLabellerIngredients
Act Buprenorphine/naloxoneActavis Pharma Company
BunavailBio Delivery Sciences International, Inc.
Buprenorphine and NaloxoneHi Tech Pharmacal Co., Inc.
Buprenorphine HCl and Naloxone HClMallinckrodt, Inc.
Buprenorphine Hydrochloride and Naloxone Hydrochloride DihydrateWest Ward Pharmaceuticals Corp
Mylan-buprenorphine/naloxoneMylan Pharmaceuticals Ulc
SuboxoneLake Erie Medical & Surgical Supply DBA Quality Care Products LLC
Teva-buprenorphine/naloxoneTeva Canada Limited
ZubsolvOrexo Us, Inc.
Salts
Name/CASStructureProperties
Buprenorphine Hydrochloride
53152-21-9
Thumb
  • InChI Key: UAIXRPCCYXNJMQ-RZIPZOSSSA-N
  • Monoisotopic Mass: 503.280236544
  • Average Mass: 504.101
DBSALT000019
Categories
UNII40D3SCR4GZ
CAS number52485-79-7
WeightAverage: 467.6401
Monoisotopic: 467.303558805
Chemical FormulaC29H41NO4
InChI KeyRMRJXGBAOAMLHD-IHFGGWKQSA-N
InChI
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
IUPAC Name
(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol
SMILES
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[[email protected]]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
Pharmacology
IndicationFor the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
Structured Indications
PharmacodynamicsBuprenorphine is a synthetic opioid analgesic and thebaine derivative, with a longer duration of action than morphine. Buprenorphine interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, buprenorphine exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Buprenorphine may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Buprenorphine depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Pharmacological effects peaks at 15 minutes and persists for 6 hours or longer when given intramuscularly. When given intravenously, the time to onset and peak effect are shortened.
Mechanism of actionBuprenorphine's analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-opioid receptor antagonist. The partial agonist activity means that opioid receptor antagonists (e.g., an antidote such as naloxone) only partially reverse the effects of buprenorphine. The binding to the mu and kappa receptors results in hyperpolarization and reduced neuronal excitability. Furthermore, buprenorphine slowly dissociates from its receptor. This observation would account for the longer duration of action compared to morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. Its receptor fixation half life is 40 minutes which is significantly longer than morphine (milliseconds).
TargetKindPharmacological actionActionsOrganismUniProt ID
Kappa-type opioid receptorProteinyes
antagonist
HumanP41145 details
Mu-type opioid receptorProteinyes
partial agonist
HumanP35372 details
Delta-type opioid receptorProteinunknown
antagonist
HumanP41143 details
Related Articles
Absorption31% bioavailability (sublingual). Sublingual absorption is also dependent on pH. The length of time the tablet is under the tongue has little effect on absorption. Although buprenorphine is rapidly absorbed from the oral mucosa, the absorption into the systemic is slower. The time to reach peak plasma concentration (Tmax) varies between individuals (range of 40 minutes to 3.5 hours). How buprenorphine is formulated does not affect this pharmacokinetic parameter. It also undergoes extensive first-pass metabolism and as a consequence, has very low oral bioavailability. Coadministration with naloxone does not effect the pharmacokinetics of buprenorphine.
Volume of distribution

Buprenorphine is very lipophillic and is thus highly distributed. The estimated volume of distribution is 188 – 335 L when given intravenously. It is able to cross into the placenta and breast milk.

Protein binding96% protein bound to alpha- and beta-globulin.
Metabolism

Hepatic. Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated by cytochrome P-450 3A4 isozyme. Norbuprenorphine, an active metabolite and has one-fifth of the pharmacologic activity of the parent compound, can further undergo glucuronidation.

SubstrateEnzymesProduct
Buprenorphine
NorbuprenorphineDetails
Buprenorphine
HydroxybuprenorphineDetails
Buprenorphine
Buprenorphine glucuronideDetails
Norbuprenorphine
Not Available
HydroxynorbuprenorphineDetails
Hydroxybuprenorphine
Not Available
HydroxynorbuprenorphineDetails
Route of eliminationBuprenorphine, like morphine and other phenolic opioid analgesics, is metabolized by the liver and its clearance is related to hepatic blood flow. It is primarily eliminated via feces (as free forms of buprenorphine and norbuprenorphine) while 10 - 30% of the dose is excreted in urine (as conjugated forms of buprenorphine and norbuprenorphine).
Half lifeIV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours); Sublingual administration = 37 hours.
Clearance

Clearance may be higher in children than in adults.
Plasma clearance rate, IV administration, anaesthetized patients = 901.2 ± 39.7 mL/min;
Plasma clearance rate, IV administration, healthy subjects = 1042 – 1280 mL/min.

ToxicityManifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Buprenorphine Action PathwayDrug actionSMP00684
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Buprenorphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Buprenorphine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Buprenorphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Buprenorphine.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Buprenorphine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Buprenorphine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Buprenorphine.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Buprenorphine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Buprenorphine.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Buprenorphine.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Buprenorphine.Approved
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Buprenorphine.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Buprenorphine.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Buprenorphine.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Buprenorphine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Buprenorphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Buprenorphine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Buprenorphine.Approved
AprepitantThe serum concentration of Buprenorphine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Buprenorphine.Approved, Investigational
ArtemetherThe metabolism of Buprenorphine can be decreased when combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Buprenorphine resulting in a loss in efficacy.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Buprenorphine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Buprenorphine.Approved
AtomoxetineThe metabolism of Buprenorphine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Buprenorphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Buprenorphine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Buprenorphine.Approved, Investigational
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
AzelastineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Azosemide.Investigational
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Buprenorphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benmoxin.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Buprenorphine.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
BetaxololThe metabolism of Buprenorphine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Buprenorphine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBuprenorphine may decrease the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Buprenorphine.Investigational
BoceprevirThe serum concentration of Buprenorphine can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Buprenorphine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Buprenorphine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Buprenorphine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buprenorphine.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Buprenorphine.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
BupropionThe metabolism of Buprenorphine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Buprenorphine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Buprenorphine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Buprenorphine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Buprenorphine.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Canrenone.Investigational
CapecitabineThe metabolism of Buprenorphine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Buprenorphine.Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Buprenorphine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Buprenorphine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Buprenorphine.Withdrawn
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ChloroquineThe metabolism of Buprenorphine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Buprenorphine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CholecalciferolThe metabolism of Buprenorphine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine.Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Buprenorphine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Buprenorphine.Approved
CinacalcetThe metabolism of Buprenorphine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Buprenorphine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Buprenorphine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Buprenorphine.Approved
ClarithromycinThe metabolism of Buprenorphine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Buprenorphine.Approved, Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ClopidogrelThe metabolism of Buprenorphine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ClotrimazoleThe metabolism of Buprenorphine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CobicistatThe serum concentration of Buprenorphine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Buprenorphine.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Buprenorphine.Approved
ConivaptanThe serum concentration of Buprenorphine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buprenorphine.Approved
CrizotinibThe metabolism of Buprenorphine can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Buprenorphine.Approved
CyclosporineThe metabolism of Buprenorphine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide.Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buprenorphine.Approved
DabrafenibThe serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Buprenorphine.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Buprenorphine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DapoxetineBuprenorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Buprenorphine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Buprenorphine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Buprenorphine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Buprenorphine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Buprenorphine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Buprenorphine.Approved
DeferasiroxThe serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Buprenorphine can be decreased when combined with Delavirdine.Approved
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.Approved
DesvenlafaxineBuprenorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
DexamethasoneThe serum concentration of Buprenorphine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Buprenorphine.Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Buprenorphine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buprenorphine.Approved
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Buprenorphine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Buprenorphine.Approved
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
DihydroergotamineThe metabolism of Buprenorphine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Buprenorphine.Illicit
DiltiazemThe metabolism of Buprenorphine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Buprenorphine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Buprenorphine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Buprenorphine.Approved, Investigational, Vet Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Buprenorphine.Approved, Investigational
DoxycyclineThe metabolism of Buprenorphine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
DronedaroneThe metabolism of Buprenorphine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
DuloxetineThe metabolism of Buprenorphine can be decreased when combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Buprenorphine.Approved
EfavirenzThe serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Buprenorphine.Approved, Investigational
EliglustatThe metabolism of Buprenorphine can be decreased when combined with Eliglustat.Approved
EluxadolineBuprenorphine may increase the constipating activities of Eluxadoline.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
EnzalutamideThe serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Buprenorphine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Eplerenone.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Buprenorphine.Approved, Investigational
ErythromycinThe metabolism of Buprenorphine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramBuprenorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Buprenorphine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Buprenorphine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Buprenorphine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Buprenorphine.Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buprenorphine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Buprenorphine.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
EtoperidoneBuprenorphine may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Buprenorphine.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Buprenorphine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Buprenorphine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Buprenorphine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FelodipineThe metabolism of Buprenorphine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Buprenorphine.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FloxuridineThe metabolism of Buprenorphine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Buprenorphine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
FluorouracilThe metabolism of Buprenorphine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Buprenorphine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Buprenorphine.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FluvastatinThe metabolism of Buprenorphine can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
FosamprenavirThe metabolism of Buprenorphine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Buprenorphine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Buprenorphine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Buprenorphine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Buprenorphine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Buprenorphine.Approved
GemfibrozilThe metabolism of Buprenorphine can be decreased when combined with Gemfibrozil.Approved
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine.Approved, Investigational, Vet Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Buprenorphine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Buprenorphine.Withdrawn
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Buprenorphine.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydracarbazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Buprenorphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Buprenorphine.Approved
IdelalisibThe serum concentration of Buprenorphine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ImatinibThe metabolism of Buprenorphine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Buprenorphine.Approved
IndalpineBuprenorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.Approved
IndinavirThe metabolism of Buprenorphine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Buprenorphine.Approved, Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid.Withdrawn
IrbesartanThe metabolism of Buprenorphine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Buprenorphine.Approved, Investigational
IsavuconazoniumThe metabolism of Buprenorphine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
IsoniazidThe metabolism of Buprenorphine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isosorbide.Approved
IsradipineThe metabolism of Buprenorphine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Buprenorphine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Buprenorphine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Buprenorphine.Approved, Vet Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
KetoconazoleThe metabolism of Buprenorphine can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Buprenorphine is combined with KW-3902.Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Buprenorphine.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Buprenorphine.Approved, Investigational
LapatinibThe metabolism of Buprenorphine can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Buprenorphine.Approved
LeflunomideThe metabolism of Buprenorphine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Buprenorphine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Buprenorphine.Approved
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Buprenorphine.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Buprenorphine.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Buprenorphine.Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Buprenorphine.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Buprenorphine.Approved
LopinavirThe metabolism of Buprenorphine can be decreased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
LorcaserinThe metabolism of Buprenorphine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.Approved
LovastatinThe metabolism of Buprenorphine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
LuliconazoleThe serum concentration of Buprenorphine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Buprenorphine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Buprenorphine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MebanazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MephedroneMephedrone may increase the analgesic activities of Buprenorphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Buprenorphine.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mersalyl.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine.Approved
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Buprenorphine.Approved
MethotrimeprazineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methylene blue.Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Buprenorphine.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Buprenorphine.Approved, Investigational
MetyrosineBuprenorphine may increase the sedative activities of Metyrosine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
MifepristoneThe serum concentration of Buprenorphine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranBuprenorphine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Buprenorphine.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MitotaneThe serum concentration of Buprenorphine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Buprenorphine.Approved, Investigational
MMDAMMDA may increase the analgesic activities of Buprenorphine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide.Approved
ModafinilThe serum concentration of Buprenorphine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
MoricizineMoricizine may increase the hypotensive activities of Buprenorphine.Approved, Withdrawn
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buprenorphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Buprenorphine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Buprenorphine.Approved
NafcillinThe serum concentration of Buprenorphine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Naloxegol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Buprenorphine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Buprenorphine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Buprenorphine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Buprenorphine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nialamide.Withdrawn
NicardipineThe metabolism of Buprenorphine can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Buprenorphine.Approved
NilotinibThe metabolism of Buprenorphine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Buprenorphine.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Buprenorphine.Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Buprenorphine.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Octamoxin.Withdrawn
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
OlaparibThe metabolism of Buprenorphine can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
OmbitasvirThe serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Buprenorphine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
OrphenadrineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
OsimertinibThe serum concentration of Buprenorphine can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buprenorphine.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Buprenorphine.Approved, Vet Approved
PalbociclibThe serum concentration of Buprenorphine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine.Approved
PanobinostatThe serum concentration of Buprenorphine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline.Approved
ParitaprevirThe serum concentration of Buprenorphine can be increased when it is combined with Paritaprevir.Approved
ParoxetineThe metabolism of Buprenorphine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.Approved
Peginterferon alfa-2bThe serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PioglitazoneThe metabolism of Buprenorphine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.Experimental
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Buprenorphine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine.Withdrawn
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Polythiazide.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Buprenorphine.Approved
PosaconazoleThe metabolism of Buprenorphine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleBuprenorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Buprenorphine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Buprenorphine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Buprenorphine.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Buprenorphine.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Buprenorphine.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Buprenorphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Buprenorphine.Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Buprenorphine.Approved, Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Buprenorphine.Approved
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Buprenorphine.Approved
PyrimethamineThe metabolism of Buprenorphine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinethazone.Approved
QuinidineThe metabolism of Buprenorphine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Buprenorphine.Approved
RabeprazoleThe metabolism of Buprenorphine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
RamosetronBuprenorphine may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Buprenorphine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Buprenorphine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
RifabutinThe metabolism of Buprenorphine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Buprenorphine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Buprenorphine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Buprenorphine.Approved, Investigational
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
RitobegronRitobegron may increase the analgesic activities of Buprenorphine.Investigational
RitonavirThe serum concentration of Buprenorphine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Buprenorphine.Approved
RolapitantThe metabolism of Buprenorphine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rolofylline.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Buprenorphine.Approved, Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
RopiniroleBuprenorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
RosiglitazoneThe metabolism of Buprenorphine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineBuprenorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Buprenorphine.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Safrazine.Withdrawn
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Buprenorphine.Approved, Vet Approved
SaquinavirThe metabolism of Buprenorphine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Buprenorphine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Buprenorphine.Approved
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
SertralineThe metabolism of Buprenorphine can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
SildenafilThe metabolism of Buprenorphine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Buprenorphine.Approved
SiltuximabThe serum concentration of Buprenorphine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Buprenorphine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Buprenorphine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Buprenorphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Buprenorphine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Buprenorphine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Buprenorphine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Buprenorphine.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Buprenorphine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Buprenorphine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Buprenorphine.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
SulfadiazineThe metabolism of Buprenorphine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Buprenorphine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
SuvorexantBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Buprenorphine.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Buprenorphine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Buprenorphine.Approved
TelaprevirThe metabolism of Buprenorphine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Buprenorphine can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Buprenorphine.Approved
TerbinafineThe metabolism of Buprenorphine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Buprenorphine can be decreased when combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
ThalidomideBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Theobromine.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Buprenorphine.Withdrawn
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Buprenorphine.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Buprenorphine.Approved
TiclopidineThe metabolism of Buprenorphine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ticrynafen.Withdrawn
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Buprenorphine.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Buprenorphine.Approved
TipranavirThe metabolism of Buprenorphine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Buprenorphine.Approved
TocilizumabThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Buprenorphine can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tolvaptan.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Buprenorphine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Buprenorphine.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Buprenorphine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Buprenorphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine.Approved
TrimethoprimThe metabolism of Buprenorphine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Buprenorphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Buprenorphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine.Approved
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ularitide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Buprenorphine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Buprenorphine.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
ValsartanThe metabolism of Buprenorphine can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Buprenorphine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Buprenorphine.Approved
VenlafaxineThe metabolism of Buprenorphine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Buprenorphine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Buprenorphine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Buprenorphine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Buprenorphine.Approved
VoriconazoleThe metabolism of Buprenorphine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
ZafirlukastThe metabolism of Buprenorphine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Buprenorphine.Approved
ZimelidineBuprenorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Vet Approved
ZolpidemBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Kazuhisa Ninomiya, Yasuhiro Fukushima, Mutsuo Okumura, Yuko Hosokawa, “Buprenorphine percutaneous absorption preparation.” U.S. Patent US6090405, issued August, 1992.

US6090405
General References
  1. Huang P, Kehner GB, Cowan A, Liu-Chen LY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001 May;297(2):688-95. [PubMed:11303059 ]
  2. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995 Feb;15(1):49-57. [PubMed:7714228 ]
  3. Elkader A, Sproule B: Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-80. [PubMed:15966752 ]
External Links
ATC CodesN02AE01N07BC01N07BC51
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelDownload (345 KB)
MSDSDownload (196 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9055
Blood Brain Barrier+0.9401
Caco-2 permeable+0.6893
P-glycoprotein substrateSubstrate0.9126
P-glycoprotein inhibitor IInhibitor0.5192
P-glycoprotein inhibitor IINon-inhibitor0.6992
Renal organic cation transporterInhibitor0.5797
CYP450 2C9 substrateNon-substrate0.8366
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.8142
CYP450 1A2 substrateNon-inhibitor0.9153
CYP450 2C9 inhibitorNon-inhibitor0.8692
CYP450 2D6 inhibitorNon-inhibitor0.6721
CYP450 2C19 inhibitorNon-inhibitor0.7801
CYP450 3A4 inhibitorNon-inhibitor0.8322
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9212
Ames testNon AMES toxic0.7448
CarcinogenicityNon-carcinogens0.9391
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1511 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Non-inhibitor0.586
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purdue pharma lp
  • Reckitt benckiser pharmaceuticals inc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Pharmaforce inc
  • Barr laboratories inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
FilmBuccal150 ug/1
FilmBuccal300 ug/1
FilmBuccal450 ug/1
FilmBuccal600 ug/1
FilmBuccal75 ug/1
FilmBuccal750 ug/1
FilmBuccal900 ug/1
FilmBuccal
InjectionIntramuscular; Intravenous.3 mg/mL
PillSublingual
TabletSublingual2 mg/1
TabletSublingual
InjectionIntramuscular; Intravenous.324 mg/mL
Injection, solutionIntramuscular; Intravenous.3 mg/mL
Injection, solutionIntramuscular; Intravenous.324 mg/mL
TabletOral2 mg/1
TabletOral8 mg/1
TabletSublingual8 mg/1
Patch, extended releaseTransdermal10 ug/h
Patch, extended releaseTransdermal15 ug/h
Patch, extended releaseTransdermal20 ug/h
Patch, extended releaseTransdermal5 ug/h
Patch, extended releaseTransdermal7.5 ug/h
PatchTransdermal10 mcg
PatchTransdermal15 mcg
PatchTransdermal20 mcg
PatchTransdermal5 mcg
ImplantSubcutaneous80 mg/1
Film, solubleBuccal; Sublingual
Film, solubleSublingual
TabletOral
Tablet, orally disintegratingSublingual
Prices
Unit descriptionCostUnit
Buprenex 0.3 mg/ml Solution (1 Box Contains Five 1ml Box)46.39USD box
Subutex 8 mg Sublingual Tabs10.2USD tab
Subutex 8 mg tablet sl9.4USD tablet
Buprenorphine 8 mg tablet sl7.74USD tablet
Buprenex 0.3 mg/ml ampul6.96USD ml
Subutex 2 mg Sublingual Tabs5.59USD tab
Subutex 2 mg tablet sl5.0USD tablet
Buprenorphine 2 mg tablet sl4.14USD tablet
Buprenorphine 0.3 mg/ml vial2.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2030178 No1995-08-152010-11-16Canada
CA2276170 No2007-12-042018-02-24Canada
US5240711 No1993-11-282010-11-28Us
US5968547 No1997-09-292017-09-29Us
US6159498 No1996-10-182016-10-18Us
US6264980 No1995-12-182015-12-18Us
US6344211 No1995-12-182015-12-18Us
US7579019 No2000-01-222020-01-22Us
US8017150 No2003-02-132023-02-13Us
US8147866 No2007-07-232027-07-23Us
US8454996 No1999-09-242019-09-24Us
US8470361 No2010-05-222030-05-22Us
US8475832 No2010-03-262030-03-26Us
US8603514 No2004-04-032024-04-03Us
US8658198 No2007-12-032027-12-03Us
US8703177 No2012-08-202032-08-20Us
US8940330 No2012-09-182032-09-18Us
US9259421 No2012-09-182032-09-18Us
USRE41408 No1997-09-292017-09-29Us
USRE41489 No1997-09-292017-09-29Us
USRE41571 No1997-09-292017-09-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.98AVDEEF,A ET AL. (1996)
pKa8.31 (at 25 °C)AVDEEF,A ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0168 mg/mLALOGPS
logP4.53ALOGPS
logP3.55ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)12.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity131.76 m3·mol-1ChemAxon
Polarizability53.11 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Azaspirodecane
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Boothby LA, Doering PL: Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007 Feb 1;64(3):266-72. [PubMed:17244875 ]
  2. Robinson SE: Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697-712. [PubMed:16953647 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Kishioka S, Paronis CA, Lewis JW, Woods JH: Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol. 2000 Mar 17;391(3):289-97. [PubMed:10729371 ]
  2. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE: Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000 Sep;23(3):326-34. [PubMed:10942856 ]
  3. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J: Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull. 2001 Jan 15;54(2):229-35. [PubMed:11275413 ]
  4. Mizoguchi H, Wu HE, Narita M, Hall FS, Sora I, Uhl GR, Nagase H, Tseng LF: Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Neuroscience. 2002;115(3):715-21. [PubMed:12435410 ]
  5. Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K: Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology. 2004 Sep;29(9):1656-63. [PubMed:15100703 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Induru RR, Davis MP: Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care. 2009 Dec-2010 Jan;26(6):470-3. doi: 10.1177/1049909109341868. Epub 2009 Aug 7. [PubMed:19666890 ]
  2. Lester PA, Traynor JR: Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res. 2006 Feb 16;1073-1074:290-6. Epub 2006 Jan 27. [PubMed:16443205 ]
  3. Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, Monier C, Noble F, Baud FJ: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006 May 1;212(3):256-67. Epub 2005 Sep 16. [PubMed:16169027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998 Aug;26(8):818-21. [PubMed:9698298 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:51